Compared to GLP-1 Agonists: Weight management peptides like semaglutide and tirzepatide have demonstrated weight loss efficacy superior to AOD-9604 in clinical trials, but they also have distinct side effect profiles
N/A, Not Available
DSIP appears to help break this cycle through multiple mechanisms
The following search string was used: #1"Parkinson Disease"[mh] OR Parkinson* [tw]) AND #2"Glucagon-Like Peptide 1"[mh] OR"GLP-1 receptor agonists"[tw] OR"glucagon-like peptide-1"[tw] OR GLP-1 [tw] OR liraglutide [tw] OR exenatide [tw] OR dulaglutide [tw] OR semaglutide [tw] OR lixisenatide [tw]) AND #3"Metabolism"[mh] OR metabolism [tw] OR"Body Weight"[mh] OR"body weight"[tw] OR"Obesity"[mh] OR obesity [tw] OR"Diabetes Mellitus"[mh] OR diabetes [tw] OR neuroprotection [tw]) AND English [la] AND ("2000"[dp]:"2025"[dp]) Study Selection The following authors, IAO and CEV, independently reviewed the titles and abstracts of all identified articles
Wegovy is an FDA-approved medication for weight management, taken once a week
Develop Monitoring Schedules for Tracking Efficacy and Side Effects Create standardized assessment protocols: Implement consistent metrics for tracking weight, HbA1c, blood pressure, lipids, and other relevant biomarkers